Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 3/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | HPGD | P15428 | 2/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | CRBN | Q96SW2 | 4/20 | 0.36 |
| ▸ | MAPT | P10636 | 2/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | PDE7A | Q13946 | 1/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.33 |
| ▸ | SSTR5 | P35346 | 1/20 | 0.33 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17057390 | 1.00 | GAA (0.40) | GAAKDM4EALDH1A1HPGDTDP1 | |
| SCHEMBL15216893 | 0.82 | LMNA (0.37) | TDP1CRBNLMNA | |
| SCHEMBL15014721 | 0.81 | CRBN (0.36) | GAAHPGDTDP1CRBNPDE7A | |
| SCHEMBL15219048 | 0.81 | PYGM (0.39) | GAAHPGDTDP1CRBNMAPK1 | |
| SCHEMBL15014726 | 0.81 | PYGM (0.39) | GAAHPGDTDP1CRBNMAPK1 | |
| SCHEMBL15219049 | 0.81 | CRBN (0.36) | GAAHPGDTDP1CRBNPDE7A | |
| SCHEMBL8256251 | 0.81 | CRBN (0.36) | GAAHPGDTDP1CRBNPDE7A | |
| SCHEMBL728294 | 0.81 | ACACB (0.39) | TDP1CRBN | |
| SCHEMBL31231783 | 0.80 | TDP1 (0.42) | GAAHPGDTDP1CRBNPDE7A | |
| SCHEMBL14609564 | 0.79 | PDE7A (0.50) | TDP1SMN1; SMN2CRBNPDE7ALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9115127-B2 | Benzimidazole and azabenzimidazole compounds that inhibit anaplastic lymphoma kinase | AMGEN INC. (US) | 2015-08-25 | — | — | US | disclosed |
| US-8907128-B2 | Boron compound with amino acid skeleton containing cyclo ring-type ring | STELLA PHARMA CORPORATION (JP) | 2014-12-09 | — | — | US | disclosed |
| US-20130225861-A1 | Boron Compound With Amino Acid Skeleton Containing Cyclo Ring | STELLA PHARMA CORPORATION (JP) | 2013-08-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130225861-A1 | Boron Compound With Amino Acid Skeleton Containing Cyclo Ring | BCAT1, BCAT2, SLC1A5 | GAA 2593/4885KDM4E 4213/4885ALDH1A1 4739/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.